OS THERAPIES INCORPORATED Financials
This page shows OS THERAPIES INCORPORATED (OSTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not operations, is carrying the company as cash burn repeatedly outruns whatever liquidity each fundraising creates.
FY2024 briefly looked liquid because financing inflow of$12.8M lifted cash to$5.5M and covered a year of losses. By FY2025, operating cash burn reached-$14.2M while cash fell to$270K , showing that the prior cushion was temporary and that the business still relies on new capital rather than internal cash generation.
Cash losses matched accounting losses in FY2025: operating cash flow was
Funding appears equity-linked: shares outstanding climbed from the prior year to 37.1M while financing cash inflow was
Financial Health Signals
OS THERAPIES INCORPORATED does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
OS THERAPIES INCORPORATED passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
OS THERAPIES INCORPORATED reported a net loss of $28.8M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
OS THERAPIES INCORPORATED's EBITDA was -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 316.1% from the prior year.
OS THERAPIES INCORPORATED reported -$28.8M in net income in fiscal year 2025. This represents a decrease of 223.7% from the prior year.
OS THERAPIES INCORPORATED earned -$0.98 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
OS THERAPIES INCORPORATED recorded an outflow of $14.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
OS THERAPIES INCORPORATED held $270K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
OS THERAPIES INCORPORATED invested $16.4M in research and development in fiscal year 2025. This represents an increase of 476.3% from the prior year.
OS THERAPIES INCORPORATED invested $466K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
OSTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| R&D Expenses | N/A | $16.4M+476.3% | $2.8M-11.7% | $3.2M |
| SG&A Expenses | N/A | $12.3M+210.6% | $4.0M+253.1% | $1.1M |
| Operating Income | N/A | -$28.7M-321.3% | -$6.8M | N/A |
| Interest Expense | N/A | N/A | $2.1M-40.5% | $3.4M |
| Net Income | N/A | -$28.8M-223.7% | -$8.9M | N/A |
| EPS (Diluted) | — | -$0.98 | -$1.28 | -$1.46 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OSTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $6.8M+23.5% | $5.5M+594.0% | $798K |
| Current Assets | $333K-94.0% | $5.5M+600.4% | $790K |
| Cash & Equivalents | $270K-95.1% | $5.5M+14095.1% | $39K |
| Total Liabilities | $11.9M+34.7% | $8.8M-64.5% | $24.8M |
| Current Liabilities | $11.8M+154.2% | $4.6M-81.3% | $24.7M |
| Total Equity | -$6.1M-86.6% | -$3.3M+86.4% | -$24.0M |
| Retained Earnings | -$67.2M-74.8% | -$38.4M-30.2% | -$29.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
OSTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$18.5M | -$14.2M-95.5% | -$7.3M-142.2% | -$3.0M |
| Capital Expenditures | N/A | $466K | N/A | N/A |
| Free Cash Flow | N/A | -$14.7M | N/A | N/A |
| Investing Cash Flow | N/A | -$466K | N/A | $1K |
| Financing Cash Flow | $15.9M | $9.4M-26.1% | $12.8M+344.7% | $2.9M |
| Dividends Paid | N/A | N/A | $2.0M | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OSTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Return on Assets | -420.4%-260.0pp | -160.4% | N/A |
| Current Ratio | 0.03-1.2x | 1.20+1.2x | 0.03 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$6.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where OS THERAPIES INCORPORATED Ranks
Frequently Asked Questions
Is OS THERAPIES INCORPORATED profitable?
No, OS THERAPIES INCORPORATED (OSTX) reported a net income of -$28.8M in fiscal year 2025.
What is OS THERAPIES INCORPORATED's EBITDA?
OS THERAPIES INCORPORATED (OSTX) had EBITDA of -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is OS THERAPIES INCORPORATED's free cash flow?
OS THERAPIES INCORPORATED (OSTX) recorded an outflow of $14.7M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OS THERAPIES INCORPORATED's operating cash flow?
OS THERAPIES INCORPORATED (OSTX) recorded an outflow of $14.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are OS THERAPIES INCORPORATED's total assets?
OS THERAPIES INCORPORATED (OSTX) had $6.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OS THERAPIES INCORPORATED's capital expenditures?
OS THERAPIES INCORPORATED (OSTX) invested $466K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does OS THERAPIES INCORPORATED spend on research and development?
OS THERAPIES INCORPORATED (OSTX) invested $16.4M in research and development during fiscal year 2025.
What is OS THERAPIES INCORPORATED's current ratio?
OS THERAPIES INCORPORATED (OSTX) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is OS THERAPIES INCORPORATED's return on assets (ROA)?
OS THERAPIES INCORPORATED (OSTX) had a return on assets of -420.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is OS THERAPIES INCORPORATED's cash runway?
Based on fiscal year 2025 data, OS THERAPIES INCORPORATED (OSTX) had $270K in cash against an annual operating cash burn of $14.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is OS THERAPIES INCORPORATED's debt-to-equity ratio negative or not reported?
OS THERAPIES INCORPORATED (OSTX) has negative shareholder equity of -$6.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is OS THERAPIES INCORPORATED's Piotroski F-Score?
OS THERAPIES INCORPORATED (OSTX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are OS THERAPIES INCORPORATED's earnings high quality?
OS THERAPIES INCORPORATED (OSTX) reported a net loss of $28.8M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.